FGFR-2 inhibitor for cholangiocarcinoma

被引：0
|
作者：
Collingridge, David
机构：
来源：
LANCET ONCOLOGY | 2022年 / 23卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E447 / E447
页数：1
相关论文
共 50 条
  • [1] Expression of FGFR-2 and FGFR-3 in the normal human fetal orbit
    Khan, SH
    Britto, JA
    Evans, RD
    Nischal, KK
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (12) : 1643 - 1645
  • [2] Tumor vascularity as a predictor of FGFR inhibitor response in FGFR2-fused intrahepatic cholangiocarcinoma.
    Meza, Kelly
    De Leon, Sergio Villegas
    Pant, Shubham
    Tang, Tin-Yun
    Meric-Bernstam, Funda
    Hu, Zishuo Ian
    Javle, Milind M.
    Lee, Sunyoung S.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [3] RELEVANCE BETWEEN FGFR-2 GENE POLYMORPHISM AND BREAST CANCER
    Wang, Yang
    Zhang, Haiyu
    Wang, Yongsheng
    ACTA MEDICA MEDITERRANEA, 2018, 34 (06): : 1717 - 1720
  • [4] FGFR-2 and Epithelial-Mesenchymal Transition in Endometrial Cancer
    Adamczyk-Gruszka, Olga
    Horecka-Lewitowicz, Agata
    Gruszka, Jakub
    Wawszczak-Kasza, Monika
    Strzelecka, Agnieszka
    Lewitowicz, Piotr
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)
  • [5] Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma
    Gile, Jennifer J.
    Wookey, Vanessa
    Zemla, Tyler J.
    Shi, Qian
    Jin, Zhaohui
    Alberts, Steven R.
    McWilliams, Robert R.
    Ma, Wen Wee
    Borad, Mitesh
    Bekaii-Saab, Tanios S.
    Tran, Nguyen H.
    Mahipal, Amit
    TARGETED ONCOLOGY, 2022, 17 (05) : 529 - 538
  • [6] ANTITUMOR ACTIVITY OF A NOVEL FGFR INHIBITOR IN INTRAHEPATIC CHOLANGIOCARCINOMA
    Raggi, Chiara
    Fiaccadori, Karim
    Pastore, Mirella
    Correnti, Margherita
    Piombanti, Benedetta
    Forti, Elisa
    Navari, Nadia
    Abbadessa, Giovanni
    Hall, Terence
    Destro, Annarita
    Di Tommaso, Luca
    Roncalli, Massimo
    Meng, Fanyin
    Glaser, Shannon S.
    Rovida, Elisabetta
    Peraldo-Neia, Caterina
    Olaizola, Paula
    Banales, Jesus M.
    Gerussi, Alessio
    Elvevi, Alessandra
    Busset, Michele Droz Dit
    Bhoori, Sherrie
    Mazzaferro, Vincenzo
    Alpini, Gianfranco
    Marra, Fabio
    Invernizzi, Pietro
    HEPATOLOGY, 2019, 70 : 226A - 227A
  • [7] Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma
    Jennifer J. Gile
    Vanessa Wookey
    Tyler J. Zemla
    Qian Shi
    Zhaohui Jin
    Steven R. Alberts
    Robert R. McWilliams
    Wen Wee Ma
    Mitesh Borad
    Tanios S. Bekaii-Saab
    Nguyen H. Tran
    Amit Mahipal
    Targeted Oncology, 2022, 17 : 529 - 538
  • [8] Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
    Lamarca, A.
    Vogel, A.
    ESMO OPEN, 2023, 8 (06)
  • [9] Antitumor Effect of the Potent FGFR Inhibitor Ponatinib on an FGFR2-Fusion Driven Cholangiocarcinoma Mouse Model
    Shaleh, Hassan M.
    Wang, Yu
    Ding, Xiwei
    Allotey, Loretta K.
    Mohamed, Essa
    Chen, Gang
    Moser, Catherine D.
    Chaiteerakij, Roongruedee
    Gozgit, Joseph
    Borad, Mitesh
    Roberts, Lewis R.
    GASTROENTEROLOGY, 2015, 148 (04) : S1017 - S1017
  • [10] FGF2 and FGFR-2 signaling stimulated Runx2 expression
    Ryoo, HM
    Kim, HJ
    Park, MH
    Shin, HI
    Kim, HJ
    BONE, 2001, 28 (05) : S148 - S148
12345